Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Intervention model: Dose Escalation (part 1) of study= Sequential Design; Dose Expansion
(part 2) of study= Parallel Design

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Clinical diagnosis of relapsed/refractory B-cell Malignancies (B-Non-Hodgkins
Lymphoma (NHL)) per International Workshop Group (IWG)

- Progressed or refractory to at least 1 prior line of standard therapy

- Subjects in Expansion cohorts are restricted to relapsed/refractory diffuse large
B-cell lymphoma (DLBCL) or Follicular Lymphoma (FL) subjects who are either relapsed
or refractory to prior rituximab or ritxumab-containing chemotherapy regimens

- Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at
screening and on treatment

- Eastern Cooperative Oncology Group (ECOG) of 0 to 1

Exclusion Criteria:

- Active or progressing brain metastases

- Other concomitant malignancies (with some exceptions per protocol)

- Active or history of autoimmune disease

- Positive test for human immunodeficiency virus (HIV) 1&2 or known Acquired immune
deficiency syndrome (AIDS)

- History of any hepatitis (A, B or C)

- History of grade 3-4 drug-related hepatitis

- Known current drug or alcohol abuse

- Active tuberculosis (TB)

- Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
including but not limited to, anti-CD137, Anti Cytotoxic T lymphocyte-associated
antigen 4 (anti-CTLA4) or Anti-Glucocorticoid-induced tumor necrosis factor receptor
(anti-GITR). However, Anti-Programmed Death-1 (anti-PD-1), Anti-Programmed
Death-Ligand1 (anti-PD-L1) are permissible as prior therapy